MYOCARDITIS: SARS-CoV-2 mRNA Vaccination-Associated Myocarditis Children Ages 12-17: A Stratified National Database Analysis; https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1 Hoeg et al.
by Paul Alexander
SERIOUS myocarditis risk in children, this is no joke, nothing as MILD myocarditis, it acts as a trojan horse and comes knocking in time
They used the Vaccine Adverse Event Reporting System (VAERS), between January 1, 2021, and June 18, 2021, among adolescents ages 12-17 who received mRNA vaccination against COVID-19.
They used symptom search criteria included the words chest pain, myocarditis, pericarditis and myopericarditis to identify children with evidence of cardiac injury.
The word troponin was a required element in the laboratory findings. Inclusion criteria were aligned with the CDC working case definition for probable myocarditis. Stratified cardiac adverse event (CAE) rates were reported for age, sex and vaccination dose number. A harm-benefit analysis was conducted using existing literature on COVID-19-related hospitalization risks in this demographic.
What did this retrospective analysis find?
They uncovered 257 cardia adverse events (CAEs).
The rates per million following dose 2 among males were 162.2 (ages 12-15) and 94.0 (ages 16-17); among females, rates were 13.0 and 13.4 per million, respectively. This placed males at far greater risk.
“For boys 12-15 without medical comorbidities receiving their second mRNA vaccination dose, the rate of CAE is 3.7 to 6.1 times higher than their 120-day COVID-19 hospitalization risk as of August 21, 2021 (7-day hospitalizations 1.5/100k population) and 2.6-4.3-fold higher at times of high weekly hospitalization risk (7-day hospitalizations 2.1/100k), such as during January 2021.
For boys 16-17 without medical comorbidities, the rate of CAE is currently 2.1 to 3.5 times higher than their 120-day COVID-19 hospitalization risk, and 1.5 to 2.5 times higher at times of high weekly COVID-19 hospitalization…Post-vaccination CAE rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence.” In other words, the risk of myocarditis is far greater post vaccine than chancing ending up in the hospital from COVID.
A key finding is that approximately 85% of these cases of myocarditis (CAE) resulted in hospitalization for both age groups.